Advertisement

Hormonal strategies in gynecologic cancer: Bridging biology and therapy

      Highlights

      • Hormonal signaling is active in gynecologic tumors and involves tumor-stroma crosstalk.
      • Progestins and aromatase inhibitors with mTOR inhibitors are clinically active in metastatic ER+/PR+ endometrial cancer.
      • Systemic or local progestins enable fertility sparing in young women with early stage endometrial cancer.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Gynecologic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Beato M.
        Gene regulation by steroid hormones.
        Cell. 1989; 56: 335-344
        • Mangelsdorf D.J.
        • Thummel C.
        • Beato M.
        • et al.
        The nuclear receptor superfamily: the second decade.
        Cell. 1995; 83: 835-839
        • Heldring N.
        • Pike A.
        • Andersson S.
        • et al.
        Estrogen receptors: how do they signal and what are their targets.
        Physiol. Rev. 2007; 87: 905-931
        • Graham J.D.
        • Clarke C.L.
        Physiological action of progesterone in target tissues.
        Endocr. Rev. 1997; 18: 502-519
        • McKenna N.J.
        • Lanz R.B.
        • O'Malley B.W.
        Nuclear receptor coregulators: cellular and molecular biology.
        Endocr. Rev. 1999; 20: 321-344
        • Chu Y.
        • Wang Y.
        • Zhang G.
        • et al.
        Chromatin composition alterations and the critical role of MeCP2 for epigenetic silencing of progesterone receptor-B gene in endometrial cancers.
        Cell. Mol. Life Sci. 2014; 71: 3393-3408
        • Sasaki M.
        • Kaneuchi M.
        • Fujimoto S.
        • et al.
        Hypermethylation can selectively silence multiple promoters of steroid receptors in cancers.
        Mol. Cell. Endocrinol. 2003; 202: 201-207
        • Yang S.
        • Jia Y.
        • Liu X.
        • et al.
        Systematic dissection of the mechanisms underlying progesterone receptor downregulation in endometrial cancer.
        Oncotarget. 2014; 5: 9783-9797
        • Singhal H.
        • Greene M.E.
        • Tarulli G.
        • et al.
        Genomic agonism and phenotypic antagonism between estrogen and progesterone receptors in breast cancer.
        Sci. Adv. 2016; 2e1501924
        • Mohammed H.
        • Taylor C.
        • Brown G.D.
        • et al.
        Rapid immunoprecipitation mass spectrometry of endogenous proteins (RIME) for analysis of chromatin complexes.
        Nat. Protoc. 2016; 11: 316-326
        • Vilgelm A.
        • Lian Z.
        • Wang H.
        • et al.
        Akt-mediated phosphorylation and activation of estrogen receptor alpha is required for endometrial neoplastic transformation in Pten+/− mice.
        Cancer Res. 2006; 66: 3375-3380
        • Bhat-Nakshatri P.
        • Wang G.
        • Appaiah H.
        • et al.
        AKT alters genome-wide estrogen receptor alpha binding and impacts estrogen signaling in breast cancer.
        Mol. Cell. Biol. 2008; 28: 7487-7503
        • Campbell R.A.
        • Bhat-Nakshatri P.
        • Patel N.M.
        • et al.
        Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance.
        J. Biol. Chem. 2001; 276: 9817-9824
        • Park S.
        • Song J.
        • Joe C.O.
        • et al.
        Akt stabilizes estrogen receptor alpha with the concomitant reduction in its transcriptional activity.
        Cell. Signal. 2008; 20: 1368-1374
        • Sanchez M.
        • Sauve K.
        • Picard N.
        • et al.
        The hormonal response of estrogen receptor beta is decreased by the phosphatidylinositol 3-kinase/Akt pathway via a phosphorylation-dependent release of CREB-binding protein.
        J. Biol. Chem. 2007; 282: 4830-4840
        • Cancer Genome Atlas Research N
        • Kandoth C.
        • Schultz N.
        • et al.
        Integrated genomic characterization of endometrial carcinoma.
        Nature. 2013; 497: 67-73
        • Kurita T.
        • Wang Y.Z.
        • Donjacour A.A.
        • et al.
        Paracrine regulation of apoptosis by steroid hormones in the male and female reproductive system.
        Cell Death Differ. 2001; 8: 192-200
        • Pineda M.J.
        • Lu Z.
        • Cao D.
        • et al.
        Influence of cancer-associated endometrial stromal cells on hormone-driven endometrial tumor growth.
        Horm. Cancer. 2015; 6: 131-141
        • Janzen D.M.
        • Rosales M.A.
        • Paik D.Y.
        • et al.
        Progesterone receptor signaling in the microenvironment of endometrial cancer influences its response to hormonal therapy.
        Cancer Res. 2013; 73: 4697-4710
        • Watanabe K.
        • Sasano H.
        • Harada N.
        • et al.
        Aromatase in human endometrial carcinoma and hyperplasia. Immunohistochemical, in situ hybridization, and biochemical studies.
        Am. J. Pathol. 1995; 146: 491-500
        • Kovats S.
        Estrogen receptors regulate innate immune cells and signaling pathways.
        Cell. Immunol. 2015; 294: 63-69
        • Kovats S.
        • Carreras E.
        • Agrawal H.
        Sex Steroid Receptors in Immune Cells.
        Springer, Berlin, Heidelberg2010
        • Hall O.J.
        • Klein S.L.
        Progesterone-based compounds affect immune responses and susceptibility to infections at diverse mucosal sites.
        Mucosal Immunol. 2017; 10: 1097-1107
        • Mutter G.L.
        • Zaino R.J.
        • Baak J.P.
        • et al.
        Benign endometrial hyperplasia sequence and endometrial intraepithelial neoplasia.
        Int. J. Gynecol. Pathol. 2007; 26: 103-114
        • Hale G.E.
        • Hughes C.L.
        • Cline J.M.
        Endometrial cancer: hormonal factors, the perimenopausal “window of risk,” and isoflavones.
        J. Clin. Endocrinol. Metab. 2002; 87: 3-15
        • Creasman W.T.
        • Soper J.T.
        • McCarty Jr., K.S.
        • et al.
        Influence of cytoplasmic steroid receptor content on prognosis of early stage endometrial carcinoma.
        Am. J. Obstet. Gynecol. 1985; 151: 922-932
        • Bokhman J.V.
        Two pathogenetic types of endometrial carcinoma.
        Gynecol. Oncol. 1983; 15: 10-17
        • Thigpen J.T.
        • Brady M.F.
        • Alvarez R.D.
        • et al.
        Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group.
        J. Clin. Oncol. 1999; 17: 1736-1744
        • Thigpen T.
        • Brady M.F.
        • Homesley H.D.
        • et al.
        Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study.
        J. Clin. Oncol. 2001; 19: 364-367
        • Isomaa V.
        • Isotalo H.
        • Orava M.
        • et al.
        Regulation of cytosol and nuclear progesterone receptors in rabbit uterus by estrogen, antiestrogen and progesterone administration.
        Biochim. Biophys. Acta. 1979; 585: 24-33
        • Kurita T.
        • Young P.
        • Brody J.R.
        • et al.
        Stromal progesterone receptors mediate the inhibitory effects of progesterone on estrogen-induced uterine epithelial cell deoxyribonucleic acid synthesis.
        Endocrinology. 1998; 139: 4708-4713
        • Fiorica J.V.
        • Brunetto V.L.
        • Hanjani P.
        • et al.
        Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study.
        Gynecol. Oncol. 2004; 92: 10-14
        • Rose P.G.
        • Brunetto V.L.
        • VanLe L.
        • et al.
        A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study.
        Gynecol. Oncol. 2000; 78: 212-216
        • Slomovitz B.M.
        • Coleman R.L.
        The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer.
        Clin. Cancer Res. 2012; 18: 5856-5864
        • Moore T.D.
        • Phillips P.H.
        • Nerenstone S.R.
        • et al.
        Systemic treatment of advanced and recurrent endometrial carcinoma: current status and future directions.
        J. Clin. Oncol. 1991; 9: 1071-1088
        • Kohorn E.I.
        Gestagens and endometrial carcinoma.
        Gynecol. Oncol. 1976; 4: 398-411
        • Fleming G.F.
        • Filiaci V.L.
        • Marzullo B.
        • et al.
        Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: a gynecologic oncology group study.
        Gynecol. Oncol. 2014; 132: 585-592
        • Slomovitz B.M.
        • Jiang Y.
        • Yates M.S.
        • et al.
        Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma.
        J. Clin. Oncol. 2015; 33: 930-936
        • Slomovitz B.M.
        • Filliaci V.L.
        • Coleman R.L.
        • Walker J.L.
        • Fleury A.C.
        • Holmy L.L.
        • Miller D.S.
        Annual Meeting of the Society of Gunecology Oncology.
        2018 (Abstract #1)
        • Gynecologists RCoOa
        Fertility sparing treatments in gynaecological oncology.
        in: Scientific Impact Paper No. 35. 2013
        • Park J.Y.
        • Lee S.H.
        • Seong S.J.
        • et al.
        Progestin re-treatment in patients with recurrent endometrial adenocarcinoma after successful fertility-sparing management using progestin.
        Gynecol. Oncol. 2013; 129: 7-11
        • Gallos I.D.
        • Shehmar M.
        • Thangaratinam S.
        • et al.
        Oral progestogens vs levonorgestrel-releasing intrauterine system for endometrial hyperplasia: a systematic review and metaanalysis.
        Am. J. Obstet. Gynecol. 2010; 203547e1-10
        • Pal N.
        • Broaddus R.R.
        • Urbauer D.L.
        • et al.
        Treatment of low-risk endometrial cancer and complex atypical hyperplasia with the levonorgestrel-releasing intrauterine device.
        Obstet. Gynecol. 2018; 131: 109-116
        • Laurelli G.
        • Falcone F.
        • Gallo M.S.
        • et al.
        Long-term oncologic and reproductive outcomes in young women with early endometrial cancer conservatively treated: a prospective study and literature update.
        Int. J. Gynecol. Cancer. 2016; 26: 1650-1657
        • Heinzelmann-Schwarz V.
        • Knipprath Meszaros A.
        • Stadlmann S.
        • et al.
        Letrozole may be a valuable maintenance treatment in high-grade serous ovarian cancer patients.
        Gynecol. Oncol. 2018; 148: 79-85
        • De Stefano I.
        • Zannoni G.F.
        • Prisco M.G.
        • et al.
        Cytoplasmic expression of estrogen receptor beta (ERbeta) predicts poor clinical outcome in advanced serous ovarian cancer.
        Gynecol. Oncol. 2011; 122: 573-579
        • Spillman M.A.
        • Manning N.G.
        • Dye W.W.
        • et al.
        Tissue-specific pathways for estrogen regulation of ovarian cancer growth and metastasis.
        Cancer Res. 2010; 70: 8927-8936
        • Andersen C.L.
        • Sikora M.J.
        • Boisen M.M.
        • et al.
        Active estrogen receptor-alpha signaling in ovarian cancer models and clinical specimens.
        Clin. Cancer Res. 2017; 23: 3802-3812
        • Hofstra L.S.
        • Mourits M.J.
        • de Vries E.G.
        • et al.
        Combined treatment with goserelin and tamoxifen in patients with advanced chemotherapy resistant ovarian cancer.
        Anticancer Res. 1999; 19: 3627-3630
        • Markman M.
        • Webster K.
        • Zanotti K.
        • et al.
        Phase 2 trial of carboplatin plus tamoxifen in platinum-resistant ovarian cancer and primary carcinoma of the peritoneum.
        Gynecol. Oncol. 2004; 94: 404-408
        • Schwartz P.E.
        • Chambers J.T.
        • Kohorn E.I.
        • et al.
        Tamoxifen in combination with cytotoxic chemotherapy in advanced epithelial ovarian cancer. A prospective randomized trial.
        Cancer. 1989; 63: 1074-1078
        • Wagner U.
        • du Bois A.
        • Pfisterer J.
        • et al.
        Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy–a phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6).
        Gynecol. Oncol. 2007; 105: 132-137
        • Argenta P.A.
        • Um I.
        • Kay C.
        • et al.
        Predicting response to the anti-estrogen fulvestrant in recurrent ovarian cancer.
        Gynecol. Oncol. 2013; 131: 368-373
        • Argenta P.A.
        • Thomas S.G.
        • Judson P.L.
        • et al.
        A phase II study of fulvestrant in the treatment of multiply-recurrent epithelial ovarian cancer.
        Gynecol. Oncol. 2009; 113: 205-209
        • Gershenson D.M.
        • Bodurka D.C.
        • Coleman R.L.
        • et al.
        Hormonal maintenance therapy for women with low-grade serous cancer of the ovary or peritoneum.
        J. Clin. Oncol. 2017; 35: 1103-1111
        • Fader A.N.
        • Bergstrom J.
        • Jernigan A.
        • et al.
        Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: reducing overtreatment without compromising survival?.
        Gynecol. Oncol. 2017; 147: 85-91
        • Farinola M.A.
        • Gown A.M.
        • Judson K.
        • et al.
        Estrogen receptor alpha and progesterone receptor expression in ovarian adult granulosa cell tumors and Sertoli-Leydig cell tumors.
        Int. J. Gynecol. Pathol. 2007; 26: 375-382
        • Madden J.D.
        • MacDonald P.C.
        Origin of estrogen in isosexual precocious pseudopuberty due to a granulosa-theca cell tumor.
        Obstet. Gynecol. 1978; 51: 210-213
        • Ameryckx L.
        • Fatemi H.M.
        • De Sutter P.
        • et al.
        GnRH antagonist in the adjuvant treatment of a recurrent ovarian granulosa cell tumor: a case report.
        Gynecol. Oncol. 2005; 99: 764-766
        • Kim H.J.
        • Lee S.C.
        • Bae S.B.
        • et al.
        GnRH agonist therapy in a patient with recurrent ovarian granulosa cell tumors.
        J. Korean Med. Sci. 2009; 24: 535-538
        • Freeman S.A.
        • Modesitt S.C.
        Anastrozole therapy in recurrent ovarian adult granulosa cell tumors: a report of 2 cases.
        Gynecol. Oncol. 2006; 103: 755-758
        • van Meurs H.S.
        • van der Velden J.
        • Buist M.R.
        • et al.
        Evaluation of response to hormone therapy in patients with measurable adult granulosa cell tumors of the ovary.
        Acta Obstet. Gynecol. Scand. 2015; 94: 1269-1275
        • Sutton G.P.
        • Stehman F.B.
        • Michael H.
        • et al.
        Estrogen and progesterone receptors in uterine sarcomas.
        Obstet. Gynecol. 1986; 68: 709-714
        • Balleine R.L.
        • Earls P.J.
        • Webster L.R.
        • et al.
        Expression of progesterone receptor A and B isoforms in low-grade endometrial stromal sarcoma.
        Int. J. Gynecol. Pathol. 2004; 23: 138-144
        • Pink D.
        • Lindner T.
        • Mrozek A.
        • et al.
        Harm or benefit of hormonal treatment in metastatic low-grade endometrial stromal sarcoma: single center experience with 10 cases and review of the literature.
        Gynecol. Oncol. 2006; 101: 464-469
        • Maluf F.C.
        • Sabbatini P.
        • Schwartz L.
        • et al.
        Endometrial stromal sarcoma: objective response to letrozole.
        Gynecol. Oncol. 2001; 82: 384-388
        • Nakamura K.
        • Nakayama K.
        • Ishikawa M.
        • et al.
        Letrozole as second-line hormonal treatment for recurrent low-grade endometrial stromal sarcoma: a case report and review of the literature.
        Oncol. Lett. 2016; 12: 3856-3860
        • Thanopoulou E.
        • Aleksic A.
        • Thway K.
        • et al.
        Hormonal treatments in metastatic endometrial stromal sarcomas: the 10-year experience of the sarcoma unit of Royal Marsden Hospital.
        Clin. Sarcoma Res. 2015; 5